Bad medicine: The way we manage diabetes

BMJ (Online)

Volumn 346, Issue 7906, 2013, Pages

  Spence, Des ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; MANAGED CARE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SHORT SURVEY; WEIGHT REDUCTION;

EID: 84877613251     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f2695     Document Type: Short Survey

References (15)

1. Cohen D, Carter P. How small changes led to big profits for insulin manufacturers. BMJ 2010;341:c7139.
2. Gale EA. Post-marketing studies of new insulins: sales or science? BMJ 2012;344:e3974.
3. National Institute for Health and Care Excellence (NICE). Blood-glucose-lowering therapy for type 2 diabetes. April 2013. http://pathways.nice.org.uk/pathways/diabetes#path=view%3A/pathways/diabetes/ blood-glucose-lowering-therapy-for-type-2-diabetes.xml&content= view-node%3Anodes-considering-triple-therapy.
4. Health and Social Care Information Centre. Prescription Cost Analysis-England, 2012. April 2013. www.hscic.gov. uk/catalogue/PUB10610.
5. Davidson MB. Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care 2005;28:1531-3. (Pubitemid 40756733)
6. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD005613.
7. Van De Laar FA, Lucassen PL, Akkermans RP, Van De Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD003639.
8. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;10:CD006423.
9. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;2:CD004654.
10. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;3:CD006063.
11. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012;12:CD009361.
12. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011;6:CD008143.
13. British National Formulary (BNF). www.bnf.org/bnf/index.htm.
14. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9.
15. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-14.